While autoimmune comorbidities in CIN are often viewed as confounding conditions for diagnosis, they may indicate a broader, systemic immune dysregulation. Adopting this perspective has direct clinical relevance. Proactive screening for associated autoimmune disorders is essential, as their presence can shape disease trajectory and modify treatment responsiveness. Furthermore, uncovering shared pathological pathways between CIN and these coexisting conditions may open avenues for therapeutic strategies that simultaneously target both neuropathic and systemic manifestations. To advance this field, future research may allow discovery of biomarkers that could stratify patients based on their distinct underlying immune drivers, which may pave the way for a precision medicine approach in this clinically heterogeneous population.
Freiha et al. (Sun,) studied this question.